



U.S. Environmental Protection Agency

Integrated Risk Information System

[Recent Additions](#) | [Contact Us](#) | [Print Version](#) Search:

[EPA Home](#) > [Browse EPA Topics](#) > [Human Health](#) > [Health Effects](#) > [IRIS Home](#) > [IRIS Summaries](#)



List of IRIS Substances

Select a Substance

- Full IRIS Summary [QuickView](#)

Chrysene (CASRN 218-01-9)

[view QuickView](#)

MAIN CONTENTS

Reference Dose for Chronic Oral Exposure (RfD)

0455

Chrysene; CASRN 218-01-9

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of chronic toxicity data by U.S. EPA health scientists from several Program Offices and the Office of Research and Development. The summaries presented in Sections I and II represent a consensus reached in the review process. Background information and explanations of the methods used to derive the values given in IRIS are provided in the Background Documents.

STATUS OF DATA FOR Chrysene

File First On-Line 12/01/1990

Category (Section)	Status	Last Revised
Oral RfD Assessment (I.A.)	no data	
Inhalation RfC Assessment (I.B.)	no data	
Carcinogenicity Assessment (II.)	on-line	03/01/1994

I. Chronic Health Hazard Assessments for Noncarcinogenic Effects

I.A. Reference Dose for Chronic Oral Exposure (RfD)

Substance Name -- Chrysene
CASRN -- 218-01-9

Not available at this time.

[Back to top](#)

Chronic Health Hazards for Non-Carcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

- [Oral RfD Summary](#)
- [Principal and Supporting Studies](#)
- [Uncertainty and Modifying Factors](#)
- [Additional Studies/Comments](#)
- [Confidence in the Oral RfD](#)
- [EPA Documentation and Review](#)

Reference Concentration for Chronic Inhalation Exposure (RfC)

- [Inhalation RfC Summary](#)
- [Principal and Supporting Studies](#)
- [Uncertainty and Modifying Factors](#)
- [Additional Studies/Comments](#)
- [Confidence in the Inhalation RfC](#)
- [EPA Documentation and Review](#)

Carcinogenicity Assessment for Lifetime Exposure

Evidence for Human Carcinogenicity

- [Weight-of-Evidence Characterization](#)
- [Human Carcinogenicity Data](#)
- [Animal Carcinogenicity Data](#)
- [Supporting Data for Carcinogenicity](#)

Quantitative Estimate of



9940

__I.B. Reference Concentration for Chronic Inhalation Exposure (RfC)

Substance Name -- Chrysene
CASRN -- 218-01-9

Not available at this time.

[Back to top](#)

[Quantitative Estimate of
Carcinogenic Risk from
Oral Exposure](#)

- [Summary of Risk
Estimates](#)
- [Dose-Response Data](#)
- [Additional Comments](#)
- [Discussion of
Confidence](#)

[Quantitative Estimate of
Carcinogenic Risk from
Inhalation Exposure](#)

- [Summary of Risk
Estimates](#)
- [Dose-Response Data](#)
- [Additional Comments](#)
- [Discussion of
Confidence](#)

[EPA Documentation,
Review and, Contacts](#)

[Bibliography](#)
[Revision History](#)
[Synonyms](#)

__II. Carcinogenicity Assessment for Lifetime Exposure

Substance Name -- Chrysene
CASRN -- 218-01-9
Last Revised -- 03/01/1994

Section II provides information on three aspects of the carcinogenic assessment for the substance in question; the weight-of-evidence judgment of the likelihood that the substance is a human carcinogen, and quantitative estimates of risk from oral exposure and from inhalation exposure. The quantitative risk estimates are presented in three ways. The slope factor is the result of application of a low-dose extrapolation procedure and is presented as the risk per (mg/kg)/day. The unit risk is the quantitative estimate in terms of either risk per ug/L drinking water or risk per ug/cu.m air breathed. The third form in which risk is presented is a drinking water or air concentration providing cancer risks of 1 in 10,000, 1 in 100,000 or 1 in 1,000,000. The rationale and methods used to develop the carcinogenicity information in IRIS are described in The Risk Assessment Guidelines of 1986 (EPA/600/8-87/045) and in the IRIS Background Document. IRIS summaries developed since the publication of EPA's more recent Proposed Guidelines for Carcinogen Risk Assessment also utilize those Guidelines where indicated (Federal Register 61(79):17960-18011, April 23, 1996). Users are referred to Section I of this IRIS file for information on long-term toxic effects other than carcinogenicity.

__II.A. Evidence for Human Carcinogenicity**__II.A.1. Weight-of-Evidence Characterization**

Classification -- B2; probable human carcinogen

Basis -- No human data and sufficient data from animal bioassays. Chrysene produced carcinomas and malignant lymphoma in mice after intraperitoneal injection and skin carcinomas in mice following dermal exposure. Chrysene produced chromosomal abnormalities in hamsters and mouse germ cells after gavage exposure, positive responses in bacterial gene mutation assays and transformed mammalian cells exposed in culture.

__II.A.2. Human Carcinogenicity Data

None. Although there are no human data that specifically link exposure to chrysene to human cancers, chrysene is a component of mixtures that have been associated with human cancer. These include coal tar, soots, coke oven emissions and cigarette smoke (U.S. EPA, 1984, 1990; IARC, 1983, 1984).

__II.A.3. Animal Carcinogenicity Data

Sufficient. Intraperitoneal chrysene injections in male mice caused an increased incidence of liver tumors (Wislocki et al., 1986; Buening et al., 1979) and increased incidences of malignant lymphoma and lung tumors (Wislocki et al., 1986). In mouse skinpainting assays chrysene tested positive in both initiation and complete carcinogen studies (Wynder and Hoffman, 1959).

On days 1, 8, and 15 of age, groups of male (28 to 35/group) and female (24 to 34/group) CD-1

mice received intraperitoneal injections of chrysene in dimethyl sulfoxide (DMSO) (total dose = 0, 160 ug or 640 ug/mouse) (Wislocki et al., 1986). The low-dose and high-dose experiments were initiated 10 weeks apart and had separate concurrent vehicle controls. Tumors were evaluated in animals that died spontaneously after weaning and in all remaining animals at 1 year after exposure. A statistically significant increase in the incidence of liver adenomas or carcinomas occurred in treated male mice relative to their respective controls: 10/35 (29%) and 5/45 (11%) in the low-dose mice and controls, respectively; and 14/34 (41%) and 2/28 (7%) in the high-dose mice and controls, respectively. The majority of the liver tumors in the high-dose males were carcinomas and the incidence was statistically significantly greater than in its respective control group, whereas the majority of tumors in the low-dose males were adenomas. Liver adenomas, but no carcinomas were observed in the control groups. In female mice no tumors were observed. The incidence of lung adenomas or carcinomas in the low-dose male mice was 6/35 (17%) (one of which was a carcinoma) and 4/45 (9%) (two of which were carcinomas) in their control group. The incidence of lung adenomas was statistically elevated in high-dose males 7/34 (21%) when compared with their control group (1/28, 4%). The incidence of malignant lymphoma was significantly elevated (3/35, 9%) in low-dose males relative to the controls (0/45), but not in the high-dose males (1/34) relative to their controls (1/28). In females, there was no statistically significant increase in lung tumors or lymphoma. This is generally regarded as a short-term exposure study with a less-than-lifetime (1 year) experiment.

Male and female Swiss Webster BLU/Ha(ICR) mice received intraperitoneal injections of chrysene in DMSO (total dose = 320 ug/mouse) or DMSO alone on days 1, 8 and 15 after birth (Buening et al., 1979). Mice were killed at 38- 42 weeks of age. The incidences of lung tumors in the treated group appeared to be elevated (5/24 (21%) and 1/11 (9%) in males and females, respectively), although not statistically significantly, when compared with the control groups (2/21 (10%) and 7/38 (18%) in males and females, respectively). The incidence of hepatic tumors in the treated males was statistically significantly greater (6/24, 25%) than in control males (0/21), whereas no hepatic tumors were found in the females. In a replication of this study, lung tumor incidence was not increased; however, the incidence of hepatic tumors in treated male mice was significantly elevated (6/27, 22%) over the incidence in the control group (0/52) (Chang et al., 1983). No liver tumors were reported in the females. These studies are regarded as short-term exposure, less-than-lifetime experiments.

Chrysene has been tested for complete carcinogenic activity and initiating activity in mouse skin painting assays. It was shown to be a complete carcinogen (Wynder and Hoffmann, 1959). Chrysene has produced positive results for initiating activity in several mouse strains (C3H, ICR/Ha Swiss, Ha/ICR/Mil Swiss, CD-1, Sencar) when applied in combination with various promoting agents (decahydronaphthalene, croton oil, TPA) producing skin papillomas and carcinomas (Van Duuren et al., 1966; Scribner, 1973; Horton and Christian, 1974; Hecht et al., 1974; Levin et al., 1978; Wood et al., 1979, 1980; Slaga et al., 1980; Rice et al., 1985).

II.A.4. Supporting Data for Carcinogenicity

Chrysene produced positive results in tests for reverse mutation in three strains of *Salmonella typhimurium* and positive results for forward mutation in one strain (McCann et al., 1975; Tokiwa et al., 1977; Wood et al., 1977; LaVoie et al., 1979; Dunkel and Simmon, 1980; Sakai et al., 1985; Kaden et al., 1979).

Chromosomal effects were observed in Chinese hamster cells, mouse oocytes and hamster spermatogonia following gavage doses of 450 or 900 mg/kg (Basler et al., 1977; Roszinsky-Kocher et al., 1979). Positive results were obtained (10 ug/mL) in tests for cell transformation in Syrian hamster embryo cells and negative results in mouse prostrate C3HG23 cells (Marquardt and Heidelberger, 1972; Pienta et al., 1977).

Current theories on mechanisms of metabolic activation of polycyclic aromatic hydrocarbons are consistent with a carcinogenic potential for chrysene. Chrysene has a "bay-region" in structure (Jerina et al., 1978). It is metabolized by mixed function oxidases to reactive "bay-region" diol epoxides (Nordqvist et al., 1981; Vyas et al., 1982) that are mutagenic in bacteria and tumorigenic in mouse skin painting assays and when injected into newborn mice (Levin et al., 1978; Wood et al., 1977, 1979; Slaga et al., 1980; Chang et al., 1983).

[Back to top](#)

II.B. Quantitative Estimate of Carcinogenic Risk from Oral Exposure

Not available.

[Back to top](#)

II.C. Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

Not available.

[Back to top](#)

II.D. EPA Documentation, Review, and Contacts (Carcinogenicity Assessment)

II.D.1. EPA Documentation

Source Document -- U.S. EPA, 1984, 1990

The 1990 Drinking Water Criteria Document for Polychlorinated Aromatic Hydrocarbons has received Agency and external review.

II.D.2. EPA Review (Carcinogenicity Assessment)

Agency Work Group Review -- 02/07/1990, 08/05/1993, 09/21/1993, 02/02/1994

Verification Date -- 02/07/1990

II.D.3. EPA Contacts (Carcinogenicity Assessment)

Please contact the IRIS Hotline for all questions concerning this assessment or IRIS, in general, at (301)345-2870 (phone), (301)345-2876 (FAX) or Hotline.IRIS@epamail.epa.gov (internet address).

[Back to top](#)

III. [reserved]

IV. [reserved]

V. [reserved]

VI. Bibliography

Substance Name -- Chrysene

CASRN -- 218-01-9

Last Revised -- 12/01/1990

VI.A. Oral RfD References

None

[Back to top](#)

VI.B. Inhalation RfC References

None

[Back to top](#)

VI.C. Carcinogenicity Assessment References

Basler, A., B. Herbold, S. Peter and G. Rohrborn. 1977. Mutagenicity of polycyclic hydrocarbons. II. Monitoring genetical Hazards of chrysene in vitro and in vivo. *Mutat. Res.* 48: 249-254.

Buening, M.K., W. Levin, J.M. Karle, H. Yagi, D.M. Jerina and A.H. Conney. 1979. Tumorigenicity of bay-region epoxides and other derivatives of chrysene and phenanthrene in newborn mice. *Cancer Res.* 39: 5063-5068.

Chang, R.L., W. Levin, A.W. Wood, et al. 1983. Tumorigenicity of enantiomers of chrysene 1,2-dihydrodiol and of the diastereomeric bay-region chrysene 1,2-diol-3,4-epoxides on mouse skin and in newborn mice. *Cancer Res.* 43: 192- 196.

Dunkel, V.C. and V.F. Simmon. 1980. Mutagenic activity of chemicals previously tested for carcinogenicity in the National Cancer Institute Bioassay Program. In: *Molecular and Cellular Aspects of Carcinogenic Screening Tests*, R. Montesano, H. Bartsch and L. Tomatis, Ed. IARC Sci. Publ. No. 27, International Agency for Research on Cancer, Lyon, France. p. 283- 301.

Hecht, S.S., W.E. Bondinell and D. Hoffmann. 1974. Chrysene and methyl chrysenes: Presence in tobacco smoke and carcinogenicity. *J. Natl. Cancer Inst.* 53: 1121-1133.

Horton, A.W. and G. M. Christian. 1974. Carcinogenic versus incomplete carcinogenic activity among aromatic hydrocarbons: Contrast between chrysenes and benzo[b]triphenylene. *J. Natl. Cancer Inst.* 53(4): 1017-1020.

IARC (International Agency for Research on Cancer). 1983. *Monographs on the Evaluation of the Carcinogenic Risk of Chemicals for Humans. Polynuclear Aromatic Compounds. Part 1. Chemical, Environmental and Experimental Data.* Vol. 32. World Health Organization.

IARC (International Agency for Research on Cancer). 1984. *Monographs on the Evaluation of the Carcinogenic Risk of the Chemical to Man. Polynuclear Aromatic Hydrocarbons. Part 3. Industrial Exposures in Aluminum Production, Coal Gasification, Coke Production, and Iron and Steel Founding.* Vol. 34. World Health Organization.

Jerina, D.M., H. Yagi, R.E. Lehr, et al., 1978. The bay-region theory of carcinogenesis by polycyclic aromatic hydrocarbons. In: *Polycyclic Hydrocarbons and Cancer, Vol. 1, Environment, Chemistry and Metabolism*, H.V. Gelboin and P.O.P. Ts'o, Ed. Academic Press, NY. p. 173-188.

Kaden, D.A., R.A. Hites and W.G. Thilly. 1979. Mutagenicity of soot and associated polycyclic

aromatic hydrocarbons to *Salmonella typhimurium*. *Cancer Res.* 39: 4152-4159.

LaVoie, E.J., E.V. Bedenko, N. Hirota, S.S. Hecht and D. Hoffmann. 1979. A comparison of the mutagenicity, tumor-initiating activity and complete carcinogenicity of polynuclear aromatic hydrocarbons. In: *Polynuclear Aromatic Hydrocarbons*, P.W. Jones and P. Leber, Ed. Ann Arbor Science Publishers, Ann Arbor, MI. p. 705-721.

Levin, W., A.W. Wood, R.L. Chang, et al. 1978. Evidence for bay region activation of chrysene 1,2-dihydrodiol to an ultimate carcinogen. *Cancer Res.* 38: 1831-1834.

Marquardt, H. and C. Heidelberger. 1972. Influence of "feeder cells" and inducers and inhibitors of microsomal mixed-function oxidases on hydrocarbon- induced malignant transformation of cells derived from C3H mouse prostate. *Cancer Res.* 32: 721-725.

McCann, J.E., E. Choi, E. Yamasaki and B.N. Ames. 1975. Detection of carcinogens as mutagens in the *Salmonella/microsome* test: Assay of 300 chemicals. *Proc. Natl. Acad. Sci. USA.* 72(12): 5135-5139.

Nordqvist, M., D.R. Thakker, K.P. Vyas, et al. 1981. Metabolism of chrysene and phenanthrene to bay-region diol epoxides by rat liver enzymes. *Mol. Pharmacol.* 19: 168-178.

Pienta, R.J., J.A. Poiley and W.B. Leberz, III. 1977. Morphological transformation of early passage golden Syrian hamster embryo cells derived from cryopreserved primary cultures as a reliable in vitro bioassay for identifying diverse carcinogens. *Int. J. Cancer.* 19: 642-655.

Rice, J.E., G.S. Mokowski, T.J. Hosted, Jr. and E. LaVoie. 1985. Methylene- bridged bay region chrysene and phenanthrene derivatives and their keto- analogs: Mutagenicity in *Salmonella typhimurium* and tumor-initiating activity on mouse skin. *Cancer Lett.* 27: 199-206.

Roszinsky-Kocher, G., A. Basler and G. Rohrborn. 1979. Mutagenicity of polycyclic hydrocarbons. V. Induction of sister-chromatid exchanges in vivo. *Mutat. Res.* 66: 65-67.

Sakai, M., D. Yoshida and S. Mizusaki. 1985. Mutagenicity of polycyclic aromatic hydrocarbons and quinones on *Salmonella typhimurium* TA97. *Mutat. Res.* 156: 61-67.

Scribner, J.D. 1973. Brief Communication: Tumor initiation by apparently noncarcinogenic polycyclic aromatic hydrocarbons. *J. Natl. Cancer Inst.* 50(6): 1717-1719.

Slaga, T.J., G.L. Gleason, G. Mills, et al. 1980. Comparison of the skin tumor-initiating activities of dihydrodiols and diol-epoxides of various polycyclic aromatic hydrocarbons. *Cancer Res.* 40: 1981-1984.

Tokiwa, H., K. Morita, H. Takeyoshi, K. Takahashi and Y. Ohnishi. 1977. Detection of mutagenic activity in particulate air pollutants. *Mutat. Res.* 48: 237-248.

U.S. EPA. 1984. Carcinogen Assessment of Coke Oven Emissions. Office of Health and Environmental Assessment, Washington, DC. EPA 600/6-82-003F. NTIS PB 84-170181.

U.S. EPA. 1990. Drinking Water Criteria Document for Polycyclic Aromatic Hydrocarbons (PAHs). Prepared by the Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Drinking Water, Washington, DC. Final Draft. ECAO-CIN-D010, September, 1990.

Van Duuren, B.L., A. Sivak, A. Segal, L. Orris and L. Langseth. 1966. The tumor promoting agents of tobacco leaf and tobacco smoke condensate. *J. Natl. Cancer Inst.* 37: 519-526.

Vyas, K.P., W. Levin, H. Yagi, et al. 1982. Stereoselective metabolism of the (+)- and (-)-enantiomers of trans-1,2-dihydroxy-1,2-dihydrochrysene to bay-region 1,2-diol-3,4-epoxide diastereomers by rat liver enzymes. *Mol. Pharmacol.* 22: 182-189.

Wislocki, P.G., E.S. Bagan, A.Y.H. Lu, et al. 1986. Tumorigenicity of nitrated derivatives of pyrene, benz[a]anthracene, chrysene and benzo[a]pyrene in the newborn mouse assay. *Carcinogenesis*. 7(8): 1317-1322.

Wood, A.W., W. Levin, D. Ryan, et al. 1977. High mutagenicity of metabolically activated chrysene 1,2-dihydrodiol: Evidence for bay region activation of chrysene. *Biochem. Biophys. Res. Commun.* 78(3): 847-854.

Wood, A.W., R.L. Chang, W. Levin, et al. 1979. Mutagenicity and tumorigenicity of phenanthrene and chrysene epoxides and diol epoxides. *Cancer Res.* 39: 4069-4077.

Wood, A.W., W. Levin, R.L. Chang, et al. 1980. Mutagenicity and tumor- initiating activity of cyclopenta(c,d)pyrene and structurally related compounds. *Cancer Res.* 40: 642-649.

Wynder, E.L. and D. Hoffmann. 1959. A study of tobacco carcinogenesis. VII. The role of higher polycyclic hydrocarbons. *Cancer.* 12: 1079-1086.

[Back to top](#)

VII. Revision History

Substance Name -- Chrysene

CASRN -- 218-01-9

Date	Section	Description
12/01/1990	II.	Carcinogen assessment on-line
12/01/1990	VI.	Bibliography on-line
01/01/1992	IV.	Regulatory Action section on-line
09/01/1993	II.	Carcinogenicity assessment noted as pending change
09/01/1993	II.D.2.	Work group review date added
11/01/1993	II.D.2.	Work group review date added
03/01/1994	II.	Pending change note removed; no change
03/01/1994	II.D.2.	Work group review date added
08/01/1995	II.D.2.	EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995.
04/01/1997	III., IV., V.	Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.

[Back to top](#)

VIII. Synonyms

Substance Name -- Chrysene

CASRN -- 218-01-9

Last Revised -- 12/01/1990

218-01-9

Chrysene
BENZ(a)PHENANTHRENE
BENZO(a)PHENANTHRENE
Chrysene
HSDB 2810
NSC 6175
RCRA WASTE NUMBER U050
1,2-BENZOPHENANTHRENE
1,2-BENZPHENANTHRENE
1,2,5,6-DIBENZONAPHTHALENE

[Back to top](#)

[What's New](#) | [Search IRIS](#) | [IRIS Home](#) | [NCEA Home](#) | [ORD Home](#)

[EPA Home](#) | [Privacy and Security Notice](#) | [Contact Us](#)

URL: <http://www.epa.gov/iris/subst/0455.htm>